Key Takeaways Bristol Myers' iberdomide showed significant MRD negativity improvement in RRMM patients.The EXCALIBER-RRMM trial showed significant MRD negativity improvement versus the control arm.The study continues to assess progression-free survival, overall survival, and safety outcomes.Bristol Myers Squibb (BMY) announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).The phase III EXCALIBER-RRMM (NCT04975997) is a multicenter, two- ...